Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
08:30am, Thursday, 17'th Apr 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
08:30am, Wednesday, 19'th Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
08:30am, Tuesday, 04'th Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
06:19pm, Friday, 14'th Feb 2025
Vistagen Therapeutics, Inc.'s results from the PALISADE-3 and PALISADE-4 studies, using fasedienol for the treatment of patients with Social Anxiety Disorder, expected in 2025. Fifth proof-of-concept
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
08:47pm, Thursday, 13'th Feb 2025
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
06:56pm, Thursday, 13'th Feb 2025
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
04:30pm, Thursday, 13'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
08:30am, Thursday, 06'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
08:30am, Wednesday, 05'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected b
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
08:30am, Friday, 10'th Jan 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollm
Vistagen to Present at the Stifel 2024 Healthcare Conference
08:30am, Thursday, 14'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
07:43am, Sunday, 10'th Nov 2024
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Princ
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
08:31pm, Thursday, 07'th Nov 2024
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
04:20pm, Thursday, 07'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
08:30am, Tuesday, 05'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry,
